Edwards Lifesciences Corp Annual Report, Year Ended Dec 31, 2023

Edwards Lifesciences Corporation (EW) demonstrated solid performance in its 2023 fiscal year, with net sales reaching $6.0 billion, an increase of 11.6% year-over-year. This growth was primarily driven by its Transcatheter Aortic Valve Replacement (TAVR) segment, which accounted for 65% of total net sales, and a significant 70.1% increase in its Transcatheter Mitral and Tricuspid Therapies (TMTT) segment. The company continues to invest heavily in research and development, with 17.8% of net sales dedicated to innovation, particularly in advancing its TAVR and TMTT platforms, including recent FDA approval for its EVOQUE tricuspid valve replacement system. While the company navigated challenges such as COVID-19 impacts and macroeconomic headwinds, its strategic focus on structural heart disease and critical care monitoring remains robust. A significant event announced in late 2023 was the planned tax-free spin-off of its Critical Care product group, expected by the end of 2024. This strategic move aims to sharpen focus and allow for expanded opportunities within its core structural heart business and interventional heart failure technologies. Investors should note the ongoing significant tax matter with the IRS concerning transfer pricing, which could have future financial implications, though the company is contesting the assessment.